A Phase 2 interventional study of Ropivacaine injection and Normal saline in Stress Disorders, Post-Traumatic, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by The University of Texas Health Science Center at San Antonio · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio — 8 open to participants now, 8 under way, none of them phase 3. Stress Disorders, Post-Traumatic · The University of Texas Health Science Center at San Antonio.
Among the 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio, this one is the 8th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 2, and was the 19th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →8 of the 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio are open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 12–20
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 49 across the 25 interventional studies, 52 across the 2 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
The University of Texas Health Science Center at San Antonio is the lead sponsor of 445 studies on the registry; 89 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 35 (54%) have results posted.
4 of the studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05423444The University of Texas Health Science Center at San AntonioNeural Connectivity During Therapy for Adolescent PTSD | 2027-02-28 |
| NCT07351305The University of Texas Health Science Center at San AntonioNon-Trauma Intervention to Treat PTSD for Veterans and Service Members Suffering From a TBI | 2027-03 |
| NCT07401225The University of Texas Health Science Center at San AntonioTMS for PTSD in Youth | 2027-06-01 |
| NCT07667309The University of Texas Health Science Center at San AntonioThe Effects of Stellate Ganglion Block Sleep in U.S. Active Duty Service Members and Veterans Receiving Prolonged Exposure Therapy for PTSD | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.
Massed PE will be conducted by master-level or doctoral-level therapists. Participants will meet with their providers for individual, 90-minute sessions. They will then be asked to complete out-of-session treatment assignments throughout the rest of the day. Between the individual therapy session and out-of-session treatment assignments, participants will engage in approximately four to six hours of treatment per day, Monday through Friday, for two weeks. Each participant will also be offered three booster sessions at 1-, 3-, and 7-weeks posttreatment.
The stellate ganglion block injection or the sham SGB will be administered between the first and second massed PE session by qualified medical personnel as per standard operating procedure for the placement of a stellate ganglion block. A research nurse will be in attendance during the procedure and for an hour recovery period following the block administration.
Assessments will be administered at pretreatment, during treatment, at posttreatment, and at 1-, 3-, and 6-months following the completion of PE. The primary outcome assessment will be 1-month following the completion of PE. Following this assessment, participants randomized to the sham SGB arm of the study will be offered an SGB with ropivacaine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One time administration of a stellate ganglion block
Drug: Ropivacaine injection
One time administration
Drug: Normal saline
6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
Also known as: Naropin
6.5cc of Normal Saline one time into the stellate ganglion.
Change from baseline in Clinician-Administered PTSD Scale-DSM 5 (CAPS-5)
A 30-item structured interview used to assess change symptoms of PTSD. Questions target the onset and duration of symptoms, subjective distress, impact on social and occupational functioning. Total severity scores range from 0 to 80 with higher score indicative of greater PTSD severity. The measure can also be used to confirm the presence of a PTSD diagnosis.
Time frame: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
Change from baseline in Posttraumatic Stress Disorder Checklist -DSM 5 (PCL-5)
A 20-item self-report measure that assesses the presence and change in severity of PTSD symptoms using the Diagnostic and Statistical Manual of mental disorders (DSM-5). Total severity scores range from 0 to 80 with higher score indictive of greater PTSD severity.
Time frame: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
Patient Health Questionnaire-9 items (PHQ-9)
A 9-item self-report measure that assesses the presence and change in severity of depressive symptoms. Total scores range from 0 to 27 with higher scores reflective of greater severity.
Time frame: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
General Anxiety Disorder Screener - 7 Items (GAD-7)
A 9-item self-report measure that assesses the presence and change in severity of general anxiety symptoms. Total scores range from 0 to 21 with higher scores reflective of greater severity.
Time frame: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
Posttraumatic Cognitions Inventory (PTCI)
A 36-item self-report measure that assesses change in self-blame, negative cognitions about self, and negative cognitions about the world following trauma exposure. Total scores range from 33 to 231 with higher scores reflective of more problematic cognitions.
Time frame: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
Psychophysiological arousal - Galvanic Skin Response
Change in Psychophysiological data collected from a smart watch measuring galvanic skin response
Time frame: Two weeks
Psychophysiological arousal - Skin Temperature
Change in Psychophysiological data collected from a smart watch measuring skin temperature
Time frame: Two weeks
Psychophysiological arousal - Heart Rate
Change in Psychophysiological data collected from a smart watch measuring heart rate
Time frame: Two weeks
Psychophysiological arousal - Interbeat Interval
Change in Psychophysiological data collected from a smart watch measuring interbeat interval
Time frame: Two weeks
Psychophysiological arousal - Three-Dimensional Accelerometer Movement
Change in Psychophysiological data collected from a smart watch measuring three-dimensional accelerometer movement
Time frame: Two weeks
Psychophysiological arousal - Electrodermal Activity
Change in Psychophysiological data collected from a smart watch measuring electrodermal activity
Time frame: Two weeks
Psychophysiological arousal - Photoplethysmography
Change in Psychophysiological data collected from a smart watch measuring photoplethysmography
Time frame: Two weeks
Plan to share: No
Started Feb 2024 (actual). Primary completion is estimated for Mar 2028, 49 months after the start.
Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's planned 49 months is close to that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Mar 2027 → Mar 2028 and completion Aug 2027 → Aug 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
Stress Disorders, Post-Traumatic →
The University of Texas Health Science Center at San Antonio →